165 related articles for article (PubMed ID: 30510411)
1. Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency.
Mostafavi B; Diaz S; Piitulainen E; Stoel BC; Wollmer P; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2018; 13():3689-3698. PubMed ID: 30510411
[TBL] [Abstract][Full Text] [Related]
2. Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of Age.
Piitulainen E; Montero LC; Nystedt-Düzakin M; Stoel BC; Sveger T; Wollmer P; Tanash HA; Diaz S
COPD; 2015 Apr; 12(2):162-7. PubMed ID: 25280185
[TBL] [Abstract][Full Text] [Related]
3. Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years.
Piitulainen E; Mostafavi B; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2017; 12():495-500. PubMed ID: 28203073
[TBL] [Abstract][Full Text] [Related]
4. CT lung densitometry in young adults with alpha-1-antitrypsin deficiency.
Bernspång E; Diaz S; Stoel B; Wollmer P; Sveger T; Piitulainen E
Respir Med; 2011 Jan; 105(1):74-9. PubMed ID: 20674322
[TBL] [Abstract][Full Text] [Related]
5. The Swedish α1-Antitrypsin Screening Study: Health Status and Lung and Liver Function at Age 34.
Tanash HA; Nystedt-Düzakin M; Montero LC; Sveger T; Piitulainen E
Ann Am Thorac Soc; 2015 Jun; 12(6):807-12. PubMed ID: 25803183
[TBL] [Abstract][Full Text] [Related]
6. Lung function in 30-year-old alpha-1-antitrypsin-deficient individuals.
Bernspång E; Wollmer P; Sveger T; Piitulainen E
Respir Med; 2009 Jun; 103(6):861-5. PubMed ID: 19181511
[TBL] [Abstract][Full Text] [Related]
7. Lung Function and Health Status in Individuals with Severe Alpha-1-Antitrypsin Deficiency at the Age of 42.
Schramm GR; Mostafavi B; Piitulainen E; Wollmer P; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2021; 16():3477-3485. PubMed ID: 34992356
[TBL] [Abstract][Full Text] [Related]
8. Liver function in alpha-1-antitrypsin deficient individuals at 37 to 40 years of age.
Mostafavi B; Diaz S; Tanash HA; Piitulainen E
Medicine (Baltimore); 2017 Mar; 96(12):e6180. PubMed ID: 28328804
[TBL] [Abstract][Full Text] [Related]
9. Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Respir Med; 2017 Sep; 130():1-8. PubMed ID: 29206626
[TBL] [Abstract][Full Text] [Related]
10. CT scan appearance, densitometry, and health status in protease inhibitor SZ alpha1-antitrypsin deficiency.
Holme J; Stockley RA
Chest; 2009 Nov; 136(5):1284-1290. PubMed ID: 19892672
[TBL] [Abstract][Full Text] [Related]
11. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD.
Green CE; Vayalapra S; Hampson JA; Mukherjee D; Stockley RA; Turner AM
Thorax; 2015 Oct; 70(10):939-45. PubMed ID: 26141072
[TBL] [Abstract][Full Text] [Related]
12. Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits.
Tanash HA; Ekström M; Rönmark E; Lindberg A; Piitulainen E
Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28889108
[TBL] [Abstract][Full Text] [Related]
13. Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency.
Bernspång E; Sveger T; Piitulainen E
Respir Med; 2007 Sep; 101(9):1971-6. PubMed ID: 17532199
[TBL] [Abstract][Full Text] [Related]
14. Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 years.
Mostafavi B; Piitulainen E; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2019; 14():525-530. PubMed ID: 30880942
[TBL] [Abstract][Full Text] [Related]
15. The liver in 30-year-old individuals with alpha(1)-antitrypsin deficiency.
Bernspång E; Carlson J; Piitulainen E
Scand J Gastroenterol; 2009; 44(11):1349-55. PubMed ID: 19891586
[TBL] [Abstract][Full Text] [Related]
16. Decline in FEV
Hiller AM; Piitulainen E; Jehpsson L; Tanash H
Int J Chron Obstruct Pulmon Dis; 2019; 14():1075-1083. PubMed ID: 31213789
[No Abstract] [Full Text] [Related]
17. Alpha1-antitrypsin deficiency in 26-year-old subjects: lung, liver, and protease/protease inhibitor studies.
Piitulainen E; Carlson J; Ohlsson K; Sveger T
Chest; 2005 Oct; 128(4):2076-81. PubMed ID: 16236857
[TBL] [Abstract][Full Text] [Related]
18. Survival in severe alpha-1-antitrypsin deficiency (PiZZ).
Tanash HA; Nilsson PM; Nilsson JA; Piitulainen E
Respir Res; 2010 Apr; 11(1):44. PubMed ID: 20420704
[TBL] [Abstract][Full Text] [Related]
19. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
20. Lung density associates with survival in alpha 1 antitrypsin deficient patients.
Green CE; Parr DG; Edgar RG; Stockley RA; Turner AM
Respir Med; 2016 Mar; 112():81-7. PubMed ID: 26874894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
